On September 16, 2024, MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, announced the closing of its upsized initial public offering. The aggregate gross proceeds from the offering were approximately $187.7 million, before deducting underwriting discounts and commissions and offering expenses. Wilson Sonsini Goodrich & Rosati advised MBX Biosciences on patent matters related to the upsized IPO.

The offering of 11,730,000 of common stock at a price to the public of $16.00 per share includes 1,530,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering.

The Wilson Sonsini team that advised MBX Biosciences on patent matters was led by Uale Taotafa and included Mike Hostetler, Nima Zargari, Jose Martinez, and T.J. O’Connor.

For more information, please see MBX Biosciences’ press release.